Baker McKenzie has advised Grundfos, a global provider of advanced pump solutions and water technologies, in connection with the future close-down of its Wahlstedt production site in the district of Segeberg. The reconciliation of interests and social plan have been concluded with the Grundfos works council. “Thanks to our expertise in connection with complex reorganizations, […]
Linklaters represented Korean LED manufacturers Seoul Semiconductor and Seoul Viosys in a successful lawsuit before the Düsseldorf Local Division of the new Unified Patent Court (UPC). With its decision, the UPC handed down a
With its ruling of 28 August 2024, Düsseldorf Higher Regional Court overturned a decision by the Federal Cartel Office (Bundeskartellamt) of 31 May 2022 in which the latter had found that a non-compete covenant agreed by STIHL with
In a landmark case, Gleiss Lutz has successfully represented Deutsche Telekom AG against the European Commission, obtaining a major victory at the Grand Chamber of the Court of Justice of the European Union (CJEU). The
Based on the survey “Global disputes forecast” conducted annually by Baker McKenzie, nearly a third of top-tier legal and risk executives in major corporations worldwide foresee an uptick in conflicts this year, with close to
For over ten years, there has been a legal battle within the confectionery cartel, reaching up to the Federal Court of Justice and back. Now, the complex concludes for three manufacturers with a total fine
Listed construction group Strabag has initiated various capital measures to push the shareholding of sanctioned Russian oligarch Oleg Deripaska to below 25 per cent. At the same time, proceedings are underway at the Klagenfurt Regional Court
Ruag, the Swiss company active in the fields of aerospace and defence, escaped a multi-million fine. On the opposite, the German company Diehl, partner of the German Bundeswehr and international armed forces, has to pay
German immunotherapy and pharmaceutical company BioNTech and its US partner Pfizer, producers of one of the Covid-19 vaccines, are trying to invalidate two patents owned by their competitor Moderna in front of the US Patent
